JP2020523038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523038A5 JP2020523038A5 JP2020518571A JP2020518571A JP2020523038A5 JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5 JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097445A JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
| JP2024205869A JP7860205B2 (ja) | 2017-06-08 | 2024-11-27 | Ｃｄ３８調節抗体 |
Applications Claiming Priority (33)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517149P | 2017-06-08 | 2017-06-08 | |
| US201762517150P | 2017-06-08 | 2017-06-08 | |
| US62/517,149 | 2017-06-08 | ||
| US62/517,150 | 2017-06-08 | ||
| US201762517745P | 2017-06-09 | 2017-06-09 | |
| US201762517740P | 2017-06-09 | 2017-06-09 | |
| US201762517164P | 2017-06-09 | 2017-06-09 | |
| US201762517753P | 2017-06-09 | 2017-06-09 | |
| US201762517734P | 2017-06-09 | 2017-06-09 | |
| US201762517165P | 2017-06-09 | 2017-06-09 | |
| US62/517,164 | 2017-06-09 | ||
| US62/517,734 | 2017-06-09 | ||
| US62/517,740 | 2017-06-09 | ||
| US62/517,165 | 2017-06-09 | ||
| US62/517,745 | 2017-06-09 | ||
| US62/517,753 | 2017-06-09 | ||
| US201762546330P | 2017-08-16 | 2017-08-16 | |
| US201762546322P | 2017-08-16 | 2017-08-16 | |
| US62/546,322 | 2017-08-16 | ||
| US62/546,330 | 2017-08-16 | ||
| US201762582616P | 2017-11-07 | 2017-11-07 | |
| US201762582676P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| US201762582681P | 2017-11-07 | 2017-11-07 | |
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582628P | 2017-11-07 | 2017-11-07 | |
| US62/582,653 | 2017-11-07 | ||
| US62/582,681 | 2017-11-07 | ||
| US62/582,628 | 2017-11-07 | ||
| US62/582,666 | 2017-11-07 | ||
| US62/582,616 | 2017-11-07 | ||
| US62/582,676 | 2017-11-07 | ||
| PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097445A Division JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523038A JP2020523038A (ja) | 2020-08-06 |
| JP2020523038A5 true JP2020523038A5 (enExample) | 2021-07-26 |
| JP7679196B2 JP7679196B2 (ja) | 2025-05-19 |
Family
ID=62620845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518571A Active JP7679196B2 (ja) | 2017-06-08 | 2018-06-08 | Ｃｄ３８調節抗体 |
| JP2023097445A Active JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097445A Active JP7596447B2 (ja) | 2017-06-08 | 2023-06-14 | Ｃｄ３８調節抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11780930B2 (enExample) |
| EP (1) | EP3635001A1 (enExample) |
| JP (2) | JP7679196B2 (enExample) |
| CN (2) | CN111051344B (enExample) |
| AU (2) | AU2018280868B2 (enExample) |
| CA (1) | CA3066547A1 (enExample) |
| WO (1) | WO2018224682A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110144008B (zh) | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| CN113727999A (zh) | 2019-01-11 | 2021-11-30 | 奥默罗斯公司 | 用于治疗癌症的方法和组合物 |
| CN114761430A (zh) * | 2019-09-26 | 2022-07-15 | 奥里尼斯生物科学股份有限公司 | 靶向pd-l1的嵌合蛋白及其用途 |
| CN114616245B (zh) * | 2019-12-13 | 2024-02-23 | 山东先声生物制药有限公司 | 一种抗cd38的抗体及其用途 |
| EP4169949A4 (en) * | 2020-06-23 | 2024-08-21 | Jiangsu Kanion Pharmaceutical Co., Ltd. | ANTI-CD38 ANTIBODY AND ITS USE |
| CN114075283A (zh) * | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| EP4211476A4 (en) * | 2020-09-10 | 2024-11-13 | CASI Pharmaceuticals, Inc. | BLOOD SCREENING PROCEDURES |
| CN116635420A (zh) * | 2020-09-10 | 2023-08-22 | 英创远达制药公司 | 血液筛查方法 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| US20260048121A1 (en) * | 2023-01-05 | 2026-02-19 | Dana-Farber Cancer Institute, Inc. | Epitope engineering of cd38 cell-surface receptors |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| ES2541436T3 (es) * | 2004-02-06 | 2015-07-20 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| PL2860192T3 (pl) | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| AU2013209322A1 (en) * | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US20100233176A1 (en) * | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| BR112012006388B1 (pt) | 2009-09-22 | 2022-01-04 | Probiogen Ag | Método para produzir uma molécula, e, método para produzir uma proteína |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| WO2015123687A1 (en) | 2014-02-14 | 2015-08-20 | Centrose, Llc | Extracellular targeted drug conjugates |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN113527495A (zh) | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CA2986594C (en) * | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| JP7628764B2 (ja) | 2015-09-29 | 2025-02-12 | アムジエン・インコーポレーテツド | Ａｓｇｒ阻害剤 |
| BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
-
2018
- 2018-06-08 EP EP18731392.9A patent/EP3635001A1/en active Pending
- 2018-06-08 CA CA3066547A patent/CA3066547A1/en active Pending
- 2018-06-08 WO PCT/EP2018/065237 patent/WO2018224682A1/en not_active Ceased
- 2018-06-08 AU AU2018280868A patent/AU2018280868B2/en active Active
- 2018-06-08 JP JP2020518571A patent/JP7679196B2/ja active Active
- 2018-06-08 CN CN201880049280.1A patent/CN111051344B/zh active Active
- 2018-06-08 US US16/620,584 patent/US11780930B2/en active Active
- 2018-06-08 CN CN202311290186.4A patent/CN117534754A/zh active Pending
-
2023
- 2023-06-14 JP JP2023097445A patent/JP7596447B2/ja active Active
- 2023-09-01 US US18/460,069 patent/US20240092928A1/en active Pending
-
2024
- 2024-11-11 AU AU2024259884A patent/AU2024259884A1/en active Pending